---
schema_version: "secwatch.filing_event.v1"
accession: "0000926326-24-000012"
form_type: "8-K"
ticker: "OMCL"
cik: "0000926326"
company_name: "OMNICELL, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T01:41:04.223886+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omnicell Q1 revenues down 15% to $246M, GAAP net loss $0.34/sh; initiates wind-down of Medimat RDS

## Summary
- Q1 GAAP revenues $246M (-15% YoY); GAAP net loss $16M ($0.34/sh) vs loss $15M ($0.33/sh) last year.
- Non-GAAP net income $1M ($0.03/sh); non-GAAP EBITDA $11M, down from $27M in Q1 2023.
- Management commits to wind down Medimat RDS product line; expects to cut >80 employees and close Bochum, Germany facility.
- Estimated nonrecurring charges $15-20M ($10-13M cash); $1.6M impairment in Q4 2023 and $3.3M severance in Q1 2024 already recorded.
- Full-year 2024 guidance unchanged: revenues $1.045-1.120B, non-GAAP EPS $0.90-1.40, non-GAAP EBITDA $90-120M.

## SEC filing metadata
- accession: 0000926326-24-000012
- form_type: 8-K
- ticker: OMCL
- cik: 0000926326
- company_name: OMNICELL, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/omcl-20240426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926326-24-000012
- JSON: https://secwatch.observer/filing/0000926326-24-000012.json
- Plain text: https://secwatch.observer/filing/0000926326-24-000012.txt

## Key facts
- Earnings Releases
  OMNICELL, INC. reported first quarter ended March 31, 2024 results: revenue $246 million, net income $16 million, or $0.34 per diluted share, EPS $0.34 per diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $246 million
  - Net income: $16 million, or $0.34 per diluted share
  - EPS: $0.34 per diluted share
  - Result: reported results
  source text: Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces First Quarter 2024 Results Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million FORT WORTH, Texas -- May 2, 2024 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy care
  evidence_url: https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm
- Restructurings & Charges
  OMNICELL, INC. announced a restructuring with charges of approximately $15 - $20 million affecting Medimat Robotic Dispensing System (RDS) product line (more than 80 employees).
  - Type: restructuring
  - Charge: approximately $15 - $20 million
  - Affected area: Medimat Robotic Dispensing System (RDS) product line
  - Headcount: more than 80 employees
  source text: once any required consent of the works council, as applicable, has finally been obtained. If the RDS Plan proceeds, the Company estimates that it will incur approximately $15 - $20 million of nonrecurring charges, of which $10 - $13 million are expected to result in future cash expenditures. The estimated nonrecurring charges consist of (i)
  evidence_url: https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.